NEW YORK (GenomeWeb News) – Life Technologies today reported that its second-quarter revenues increased 2 percent, or 7.5 percent excluding the impact from currency exchange, on strong gains for its Molecular Biology Systems and Genetic Systems divisions.

The firm, which was formed by last year's merger of Invitrogen and Applied Biosystems, reported non-GAAP revenues of $839.1 million for the three-month period ended June 30, compared to non-GAAP revenues of $821.6 million for the combined firms, which were separate entities for the comparable period a year ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.